• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

    1/27/25 7:55:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email

    Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR® AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs). The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%, with several recently approved ADCs achieving blockbuster status with annual sales exceeding $1 billion. Major biotech and pharmaceutical companies have recently completed ADC-focused acquisitions valued at over $10 billion, highlighting the sector's growing strategic importance. Lantern Pharma is actively advancing multiple ADC candidates through preclinical development, including a promising collaboration with the prestigious MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany.

    In a peer-reviewed study published in PLOS ONE, Lantern Pharma researchers demonstrated how their AI-driven approach successfully identified 82 promising ADC targets and 290 target-indication combinations, while also validating 729 potential payload molecules from a screening of over 50,000 compounds. Notably, 22 of these targets have already been validated in clinical or preclinical settings, demonstrating the platform's ability to identify clinically relevant targets. The remaining 60 novel targets represent significant potential for new intellectual property, portfolio development of ADC candidates at Lantern Pharma and licensing opportunities with other biotech and pharma companies. The ADC module helped to characterize payload molecules with exceptional potency, exhibiting GI50 values from picomolar to 10 nM (nanomolar) ranges. These payload molecules can be further optimized by leveraging RADR's comprehensive molecular features database by mapping drug-response relationships with biochemical and molecular structure characteristics. This AI-driven optimization capability could potentially enhance both the selective targeting and therapeutic window of these ADC payload candidates. Lantern Pharma continues to advance the methods and automations outlined in the paper as part of it's RADR™ AI platform and further enhance the data and computational precision of the module.

    "This breakthrough demonstrates how AI can transform the traditionally costly and time-consuming process of ADC development," said Panna Sharma, CEO & President of Lantern Pharma. "By simultaneously analyzing multiple data types and integrating mutation profiles with target expression, our team was able to identify optimal therapeutic combinations that have the potential to be more effective and safer for specific patient populations. We believe that our data-driven and machine-learning ready approach could reduce ADC development timelines by 30 to 50% and cut associated costs by up to 60% compared to traditional methods of ADC development."

    The research leverages Lantern's proprietary RADR® platform to analyze complex datasets including transcriptomics, proteomics, and mutation profiles across 22 tumor types. The platform's ability to predict mutation-specific responses could enable more precise patient stratification in clinical trials, potentially increasing success rates and reducing development costs. This precision approach to ADC development could be valuable for biotech and pharmaceutical companies looking to advance their ADC portfolio in more targeted indications and is also being actively used by Lantern in the development and modeling of their ADC candidates in preclinical testing and optimization.

    "The implications of this research extend far beyond just expanding the repertoire of potential ADC targets," said Kishor Bhatia, Ph.D., Chief Scientific Officer at Lantern Pharma. "By leveraging our RADR® platform's advanced AI capabilities, we've created a systematic approach that could dramatically reduce both the time and cost of ADC development while increasing the probability of clinical success. Our platform is particularly well-suited for partnership opportunities with pharmaceutical companies looking to accelerate their ADC programs or expand their pipeline with novel targets."

    Key Highlights of the AI-powered ADC module include:

    • Demonstrated platform validation through the successful identification of 22 clinically proven targets with established therapeutic potential
    • Discovered 60 novel targets that present significant opportunities for new intellectual property development, portfolio expansion, and strategic licensing partnerships
    • Developed proprietary mutation-specific targeting capabilities that enable improved clinical trial design, enhanced precision in indication selection, and more accurate patient response predictions
    • Established a framework that could reduce ADC development costs by up to 60% and accelerate development timelines by 30-50% for both Lantern Pharma and its collaborators
    • Created a highly scalable, machine-learning ready approach that leverages the RADR™ AI platform to systematically evaluate thousands of potential tumor sub-types and indications
    • Designed a clear pathway to commercialization through strategic industry partnerships and collaborative development programs

    The complete research paper, titled "Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis," is available in PLOS ONE at https://doi.org/10.1371/journal.pone.0308604. The paper outlines the approach and initial data-sets used in the development of the AI-powered ADC development module which continues to be enhanced, and is being further validated by Lantern Pharma.

    About Lantern Pharma

    Lantern Pharma (NASDAQ:LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.

    Please find more information at:

    • Website: www.lanternpharma.com
    • LinkedIn: https://www.linkedin.com/company/lanternpharma/
    • X: @lanternpharma

    FORWARD LOOKING STATEMENT:

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250127132783/en/

    Investor Relations

    [email protected]

    (972)277-1136

    Get the next $LTRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

      Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, today announced promising preclinical data for LP-184 in atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer. The results were presented by Dr. Eric Raabe of Johns Hopkins University School of Medicine at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Co

      5/29/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

      Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

      5/15/25 8:45:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

      Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. The FDA has cleared the LP-184 investigational new drug (IND) application amendment for the treatment of a biomarker defined patient population of non-small cell lung cancer (NSCLC). The planned phase 1b/2 clinical trial plans to evaluate LP-184 in advanced NSCLC patients with KEAP1 and/or STK11 mutations and low expression of PD-L1 in combination with the immune checkpoint inhibitor therapies, nivolumab and ipilimumab. LP-184 is a synthetically lethal, novel small molecule advanced and developed with La

      5/12/25 9:00:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

      SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

      3/1/24 4:10:40 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

      SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

      2/14/24 4:05:49 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

      SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

      12/1/23 6:02:25 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

      DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

      9/2/21 8:59:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    SEC Filings

    See more
    • SEC Form 144 filed by Lantern Pharma Inc.

      144 - Lantern Pharma Inc. (0001763950) (Subject)

      5/27/25 9:00:02 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Lantern Pharma Inc.

      144 - Lantern Pharma Inc. (0001763950) (Subject)

      5/27/25 8:58:37 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Lantern Pharma Inc.

      144 - Lantern Pharma Inc. (0001763950) (Subject)

      5/27/25 8:56:44 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Fletcher Aaron G.L. sold $168,419 worth of shares (56,237 units at $2.99) (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      5/29/25 9:55:55 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Kreis Leslie W. sold $168,419 worth of shares (56,237 units at $2.99) (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      5/29/25 9:53:24 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Keyser D Jeffrey exercised 3,832 in-the-money shares at a strike of $3.13 (SEC Form 4)

      4 - Lantern Pharma Inc. (0001763950) (Issuer)

      7/26/24 4:15:16 PM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

      3/11/22 6:29:59 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

      11/2/21 6:34:51 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

      10/7/21 8:16:17 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LTRN
    Financials

    Live finance-specific insights

    See more
    • Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

      Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

      5/15/25 8:45:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

      Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

      5/8/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care